MedWatch

Prominent investors criticize Lundbeck's share structure split

Pharmaceutical firm Lundbeck’s recently proposed split share structure has not been well received by some big investors.

Photo: Lundbeck / PR

Last week, Lundbeck announced a new share structure dividing shares into two categories, which would allow the company to hunt for external financing without the Lundbeck Foundation, which is the majority shareholder, having to relinquish any power.

The news has been met with criticism from a string of pension funds and private investors, as reported by Danish media Berlingske.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs